| Literature DB >> 26643452 |
Lucilla Parnetti1, Claudia Cicognola2, Paolo Eusebi3, Davide Chiasserini1.
Abstract
Since diagnosis of Parkinson's disease (PD) is mostly based on clinical criteria, it is almost impossible to formulate an early diagnosis, as well as a timely differential diagnosis versus other parkinsonisms. A great effort in searching reliable biomarkers both for early diagnosis and prognosis in PD is currently ongoing. Cerebrospinal fluid has been widely investigated as potential source for such biomarkers, with particular emphasis on α-synuclein (α-syn) species. We reviewed all the clinical studies carried out so far on cerebrospinal fluid quantification of α-syn species in PD. Current evidence supports the value of total and oligomeric α-syn in PD diagnosis and in the differential diagnosis of PD and other parkinsonisms. Conversely, the role of α-syn species in PD prognosis remains unsatisfactory.Entities:
Keywords: Parkinson's disease; cerebrospinal fluid biomarkers; cognitive impairment; disease progression; early diagnosis; motor symptoms; parkinsonisms; prognosis; α-synuclein
Mesh:
Substances:
Year: 2015 PMID: 26643452 DOI: 10.2217/bmm.15.107
Source DB: PubMed Journal: Biomark Med ISSN: 1752-0363 Impact factor: 2.851